Security
EOLS · Evolus, Inc.
EOLSNASDAQCommon stockCurrentCIK 1570562Updated Sep 27, 2026
Name history
Evolus, Inc. · through Sep 4, 2026
EOLS price & chart
Loading TradingView…
NASDAQ:EOLS on TradingView ↗About the company
Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics by building a differentiated portfolio of injectable brands that address the evolving needs of practitioners and patients. Our portfolio includes Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, Evolysse®, a collection of unique injectable hyaluronic acid (HA) gels, and Profhilo®, the market-leading injectable for skin quality in Europe, which Evolus has exclusively licensed for development and commercialization in the United States. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.
In the news
No coverage from other publishers is available.
Recent filings
144 filing
SCHEDULE 13G filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Items 1.01, 7.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 225,868,000Source | 232,569,000Source | 188,998,000Source | 177,983,000Source |
| Property, Plant and Equipment, NetUSD | 5,371,000Source | 3,222,000Source | 2,087,000Source | 2,616,000Source |
| GoodwillUSD | 21,208,000Source | 21,208,000Source | 21,208,000Source | 21,208,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 48,040,000Source | 48,754,000Source | 47,110,000Source | 48,597,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 53,826,000Source | 86,952,000Source | 62,838,000Source | 53,922,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 54,697,000Source | 47,682,000Source | 30,529,000Source | 22,448,000Source |
| Inventory, NetUSD | 26,963,000Source | 12,158,000Source | 10,998,000Source | 18,852,000Source |
| Assets, CurrentUSD | 142,917,000Source | 151,342,000Source | 112,421,000Source | 100,802,000Source |
| Operating Lease, Right-of-Use AssetUSD | 7,133,000Source | 7,185,000Source | 5,763,000Source | 1,947,000Source |
| Other Assets, NoncurrentUSD | 1,199,000Source | 858,000Source | 409,000Source | 2,813,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 248,974,000Source | 227,047,000Source | 209,687,000Source | 159,484,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 1,000Source | 1,000Source | 1,000Source | 1,000Source |
| Additional Paid in CapitalUSD | 638,089,000Source | 615,825,000Source | 538,716,000Source | 516,129,000Source |
| Retained Earnings (Accumulated Deficit)USD | -661,040,000Source | -609,399,000Source | -558,979,000Source | -497,294,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -156,000Source | -905,000Source | -427,000Source | -337,000Source |
| Stockholders' Equity Attributable to ParentUSD | -23,106,000Source | 5,522,000Source | -20,689,000Source | 18,499,000Source |
| Liabilities and EquityUSD | 225,868,000Source | 232,569,000Source | 188,998,000Source | 177,983,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 75,305,000Source | 62,960,000Source | 48,291,000Source | 46,509,000Source |
| Operating Lease, Liability, CurrentUSD | 2,529,000Source | 1,718,000Source | 1,377,000Source | 1,320,000Source |
| Accounts Payable, CurrentUSD | 23,360,000Source | 9,236,000Source | 4,271,000Source | 8,935,000Source |
| Operating Lease, Liability, NoncurrentUSD | 6,371,000Source | 6,755,000Source | 4,810,000Source | 1,224,000Source |
| Deferred Income Tax Liabilities, NetUSD | 28,000Source | 6,000Source | 27,000Source | 22,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 35,591,000Source | 40,791,000Source | 33,813,000Source | 24,794,000Source |
| Deferred Tax Liabilities, NetUSD | 28,000Source | 6,000Source | 27,000Source | 22,000Source |
| Long-term DebtUSD | 146,096,000Source | 121,506,000Source | 120,359,000Source | 71,879,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 7,506,000Source | 5,297,000Source | 5,133,000Source | 3,722,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 20,698,000Source | 22,254,000Source | 16,458,000Source | 10,833,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 11,509,000Source | 19,602,000Source | 9,521,000Source | 9,389,000Source |
| Increase (Decrease) in InventoriesUSD | 11,124,000Source | -3,252,000Source | -4,193,000Source | 10,688,000Source |
| Increase (Decrease) in Accounts PayableUSD | 10,103,000Source | 391,000Source | -1,017,000Source | 968,000Source |
| Deferred Income Tax Expense (Benefit)USD | 21,000Source | -21,000Source | 5,000Source | -18,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -42,265,000Source | -17,999,000Source | -34,008,000Source | -84,912,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -8,452,000Source | -4,823,000Source | -1,627,000Source | -2,939,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 3,441,000Source | 1,472,000Source | 473,000Source | 1,618,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 0Source | 990,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 17,337,000Source | 47,414,000Source | 44,641,000Source | -4,146,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -33,126,000Source | 24,114,000Source | 8,916,000Source | -92,334,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 53,826,000Source | 86,952,000Source | 62,838,000Source | 53,922,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 14,792,000Source | 17,545,000Source | 12,708,000Source | 7,999,000Source |
| Income Taxes Paid, NetUSD | 1,215,000Source | 235,000Source | 117,000Source | 76,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 254,000Source | -478,000Source | -90,000Source | -337,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 20,698,000Source | 22,188,000Source | 16,458,000Source | 10,833,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 1,289,000Source | 1,147,000Source | 1,116,000Source | 1,086,000Source |
| Amortization of Intangible AssetsUSD | 6,273,000Source | 4,104,000Source | 4,072,000Source | 3,350,000Source |
| DepreciationUSD | 1,233,000Source | 1,194,000Source | — | — |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | 0Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | 0Source |
| GoodwillUSD | 21,208,000Source | 21,208,000Source | 21,208,000Source | 21,208,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | 0Source | 0Source | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | 677,000Source | 664,000Source | 176,000Source | 95,000Source |
| InterestExpenseNonoperatingUSD | 19,694,000Source | 18,735,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -51,641,000Source | -50,420,000Source | -61,685,000Source | -74,412,000Source |
| Other Nonoperating Income (Expense)USD | -539,000Source | 127,000Source | 696,000Source | -9,000Source |
| Proceeds from Issuance of Common StockUSD | 0Source | 51,211,000Source | — | — |
| Proceeds from Issuance of Long-term DebtUSD | — | 0Source | 50,000,000Source | — |
| Proceeds from Stock Options ExercisedUSD | — | 4,882,000Source | — | — |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | 20,796,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 297,176,000Source | 266,274,000Source | 202,085,000Source | 148,616,000Source |
| Cost of RevenueUSD | 100,069,000Source | 83,970,000Source | 61,559,000Source | 55,887,000Source |
| Selling, General and Administrative ExpenseUSD | 220,786,000Source | 198,025,000Source | 164,944,000Source | 141,840,000Source |
| Operating Income (Loss)USD | -32,662,000Source | -34,411,000Source | -49,233,000Source | -65,330,000Source |
| Other Nonoperating Income (Expense)USD | -539,000Source | 127,000Source | 696,000Source | -9,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -50,964,000Source | -49,756,000Source | -61,509,000Source | -74,317,000Source |
| Income Tax Expense (Benefit)USD | 677,000Source | 664,000Source | 176,000Source | 95,000Source |
| Net Income (Loss) Attributable to ParentUSD | -51,641,000Source | -50,420,000Source | -61,685,000Source | -74,412,000Source |
| Earnings Per Share, BasicUSD per share | -0.8Source | -0.81Source | -1.08Source | -1.33Source |
| Earnings Per Share, DilutedUSD per share | -0.8Source | -0.81Source | -1.08Source | -1.33Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 64,468,913Source | 62,016,853Source | 56,918,721Source | 56,065,297Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 64,468,913Source | 62,016,853Source | 56,918,721Source | 56,065,297Source |
| Interest Expense (non-operating)USD | 19,694,000Source | 18,735,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 6,273,000Source | 4,104,000Source | 4,072,000Source | 3,350,000Source |
| Cost, Depreciation and AmortizationUSD | — | 2,342,000Source | — | — |
| Costs and ExpensesUSD | 229,769,000Source | 216,715,000Source | 251,318,000Source | 213,946,000Source |
| Current Income Tax Expense (Benefit)USD | 656,000Source | 685,000Source | 171,000Source | 113,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 4,345,000Source | — | — | — |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | 0Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Gross ProfitUSD | 197,107,000Source | 182,304,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -30,131,000Source | -33,349,000Source | -51,004,000Source | -66,103,000Source |
| Interest ExpenseUSD | — | — | 13,832,000Source | 9,097,000Source |
| Investment Income, NetUSD | 1,931,000Source | 3,263,000Source | 860,000Source | 119,000Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | 20,796,000Source | — | — | — |
Filing attachments
q22026eolsex991.htm · 8-K · 2026-08-05
EX-99.1 2 q22026eolsex991.htm EX-99.1 Document Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook • Global Net Revenue of $84.1 Million for the Second Quarter of 2026, an Increase of 21% Over the Prior Year, Reflecting Increasing Market Share Gains Across U.S. and International Markets • GAAP Operating Loss of $4.5 Million and Positive Adjusted EBITDA of $4.7 Million for th…
Read attachment ↗a8k8426ex991.htm · 8-K · 2026-08-04
EX-99.1 2 a8k8426ex991.htm EX-99.1 Document Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand Establishes a complementary injectable hyaluronic acid (HA) gel portfolio alongside Jeuveau® and Nuceiva® across all Evolus commercial markets Further leverages Evolus’ international commercial infrastructure to support long-term profitable growth NEWPORT BEACH, Calif., August 4, 2026 - Evolus, Inc. (NASDAQ: EOLS), a global performa…
Read attachment ↗a78268kex991.htm · 8-K · 2026-07-08
EX-99.1 2 a78268kex991.htm EX-99.1 Document Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality NEWPORT BEACH, Calif., July 8, 2026 - Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has entered into an exclusive licensing and distribution agreement with IBSA, a Swiss multin…
Read attachment ↗q12026eolsex991.htm · 8-K · 2026-05-04
EX-99.1 2 q12026eolsex991.htm EX-99.1 Document Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook • Global Net Revenue of $73.1 Million for the First Quarter of 2026, Up 7% Over the Prior Year and Against the Highest Growth Quarter of 2025 • GAAP Operating Loss of $6.8 Million and Adjusted EBITDA of $0.6 Million for the First Quarter of 2026, Representing the Second Consecutive Quarte…
Read attachment ↗q42025eolsex991.htm · 8-K · 2026-03-03
EX-99.1 3 q42025eolsex991.htm EX-99.1 Document Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026 • Total Net Revenue of $90.3 Million for the Fourth Quarter and $297.2 Million for the Full-Year 2025, Representing Growth of 14% and 12% Over the Prior Year • Delivered GAAP Operating Income of $4.2 Million for the Fourth Quarter; Non-GAAP Operating Income of $7.1 …
Read attachment ↗q32025eolsex991.htm · 8-K · 2025-11-05
EX-99.1 2 q32025eolsex991.htm EX-99.1 Document Evolus Reports Third Quarter 2025 Financial Results • Total Net Revenue of $69.0 Million for Q3 2025, Up 13% from Q3 2024; Year-To-Date Growth of 10% • Global Jeuveau® Net Revenue of $63.2 Million for Q3 2025, Up from $59.7 Million in Q2 2025, Reflecting Sequential Growth That Outperformed Typical Seasonal Trends • Evolysse™ Delivered $5.7 Million in Revenue for Q3 2025 Marking the Strongest Hyaluronic Acid (HA) Filler Debut in Over a Decade…
Read attachment ↗